Janice Reichert, PhD
Position:
Research Assistant Professor
Phone:
617-636-2182
E-mail:
.(JavaScript must be enabled to view this email address)
Area of Expertise
Evaluation of technology platforms and partnering/market potential for therapeutics and vaccines, including those for cancer, immunological disorders, pain and infectious disease; evaluation of the biopharmaceutical industry’s pipeline of targeted therapeutics, including antibody-based and peptide clinical candidates.
| Faculty Summary | Recently Completed Research Projects |
|
| Dr. Reichert has studied innovation in the pharmaceutical and biotechnology industries at the Center for the Study of Drug Development (CSDD) since 1999. She is also Founder and Editor-in-Chief of mAbs, a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development; President of the board of directors of The Antibody Society; and a member of the board of the Peptide Therapeutics Foundation. At CSDD, Dr. Reichert’s work focuses on strategic analyses of investigational candidates and marketed products, with emphasis on the clinical development and approval of new therapeutics and vaccines. Dr. Reichert has published extensively on these topics, and she has presented her research results as an invited speaker at conferences located world-wide. |
|
Current Research Initiatives
- Success rates for oncology drugs
- Antibody therapeutics global pipeline evaluation
- Peptide therapeutics global pipeline evaluation
Selected Publications
| 1. | Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs. 2011; 3(1):76-99. |
| 2. | Reichert JM. Metrics for antibody therapeutics development. MAbs. 2010; 2(6):695-700. |
| 3. | Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nature Reviews Drug Discovery 9(10):767-74 (2010). |
| 4. | Reichert JM. Antibodies to watch in 2010. MAbs. 2010; 2(1):84-100. |
| 5. | Reichert JM. Probabilities of success for antibody therapeutics. MAbs. 2009; 1(4):387-9. |
| 6. | Reichert JM. Global trends in antibody development. MAbs. 2009; 1(1):86-7. |
| 7. | Saladin PM, Zhang BD, Reichert JM. Current trends in the clinical development of peptide therapeutics. IDrugs 12(12):779-84 (2009). |
| 8. | Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nature Biotechnology 27(4):331-337 (2009). |
| 9. | Reichert JM, Rochon SL, Zhang BD. A decade of the Fast Track programme. Nature Reviews Drug Discovery 7(11):885-886 (2008). |
| 10. | Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discovery Today 13(1-2):30-37 (2008). |
| 11. | Reichert JM, Valge-Archer V. Development trends for monoclonal antibody cancer therapeutics. Nature Reviews Drug Discovery, 6(5):349-356 (2007). |
| 12. | Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nature Biotechnology 23(9):1073-1078 (2005). |
Board Memberships and Affiliations
- Editor-in-Chief, mAbs (2008-present)
- President (2012), Vice-President (2010-11), Board of Directors, The Antibody Society
- Member, Board of Directors, Peptide Therapeutics Foundation (2008-present)
- Co-chair, Clinical Trials Committee, Massachusetts Biotechnology Council (2002-2007)
- Advisory Editorial Board, Drug Discovery Today (2003-present)
- Editorial Board, Protein Engineering, Design and Selection (2009-present)
- International Editorial Advisory Board, Generics and Biosimilars Initiative Journal (2010-present)